Belite Bio Announces Additional Secondary Endpoint Data From Phase 3 DRAGON Trial Of Tinlarebant In Stargardt Disease, Presented At ASRS 2026 In Montréal

뉴스 본문을 불러오고 있어요.

Belite Bio Announces Additional Secondary Endpoint Data From Phase 3 DRAGON Trial Of Tinlarebant In Stargardt Disease, Presented At ASRS 2026 In Montréal | 웨이프 WAPE

Belite Bio Announces Additional Secondary Endpoint Data From Phase 3 DRAGON Trial Of Tinlarebant In Stargardt Disease, Presented At ASRS 2026 In Montréal

기사 요약

관련 종목

댓글 —